NasdaqGS:GILDBiotechs
Gilead Advances HIV And Oncology Pipeline As Shares Trade Below Targets
Gilead Sciences (NasdaqGS:GILD) received FDA acceptance and priority review for its New Drug Application for a once daily HIV regimen.
The company also completed its acquisition of Arcellx, gaining full control of a multiple myeloma CAR T cell therapy program.
Both developments relate to core franchises for Gilead, HIV and oncology, and come as the company continues to focus on therapies for serious diseases.
Gilead is widely associated with antiviral treatments, including HIV therapies,...